2015-003537-99
A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis
F. Hoffmann-La Roche AG·EU Clinical Trials Register
Study focus
- Disease/Condition
- Cystic Fibrosis
Sponsor & location
- Primary sponsor
- F. Hoffmann-La Roche AG
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
- An acute respiratory infection or pulmonary exacerbation within 4 weeks prior to randomization
ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2015-003537-99
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2015-003537-99 through Pure Global AI's free database. This phase not specified trial is sponsored by F. Hoffmann-La Roche AG and is currently status unknown. The study focuses on Cystic Fibrosis.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.